US Patent 8,709,491: Scope, Claims, Expiration, Orange Book Status, and Competitive Patent Landscape
US Patent 8,709,491 protects a multipart pharmaceutical composition containing mixed amphetamine salts complexed with ion-exchange resin particles. Its core limitation is a specific blend of uncoated and delayed-release drug-resin particles: 20% to 50% uncoated particles and 50% to 80% coated particles. The preferred embodiment uses approximately 45% uncoated and 55% pH-triggered, delayed-release particles.
The patent is associated with Tris Pharma’s extended-release amphetamine products, including Dyanavel XR. The patent issued on April 29, 2014, and has a reported expiration date of March 12, 2028, subject to any applicable patent-term adjustments or corrections recorded by the USPTO or FDA. [1, 2]
What does US Patent 8,709,491 protect?
The patent protects a dosage-form architecture rather than amphetamine as a molecule. The protected architecture combines:
- Dextro-amphetamine and levo-amphetamine.
- Ion-exchange resin particles carrying the amphetamine.
- A population of uncoated drug-resin particles.
- A second population of drug-resin particles with delayed-release coatings.
- Defined percentage ranges for the two particle populations.
Claim 1 is the controlling independent composition claim. A product must contain each of those elements to fall within the literal scope of the claim.
| Claim element |
Scope |
| Active ingredient |
Mixture of dextro- and levo-amphetamines |
| Drug carrier |
Ion-exchange resin particles |
| First particle population |
Uncoated drug-resin particles |
| First population amount |
20% to 50% |
| Second particle population |
Drug-resin particles with delayed-release coating |
| Second population amount |
50% to 80% |
| Dosage-form limitations |
Added in dependent claim 7 |
| Stereochemical ratio |
25% levo-amphetamine and 75% dextro-amphetamine in claim 8 |
| Dose limitation |
2 mg to 60 mg of ADHD-effective agent in claim 9 |
The patent does not broadly cover every extended-release amphetamine formulation. A formulation using polymer-coated beads without ion-exchange resin, a formulation containing only one amphetamine enantiomer, or a formulation that does not have the claimed uncoated/coated particle combination would present a stronger non-infringement position.
How do the claims of US 8,709,491 operate?
Claim 1: Core composition claim
Claim 1 requires a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles. The resulting particles must be divided into two populations:
- 20% to 50% uncoated drug-resin particles; and
- 50% to 80% drug-resin particles with a delayed-release coating.
The percentages are central limitations. A product containing 10% uncoated particles and 90% coated particles would fall outside the literal numerical ranges of claim 1. A product containing 60% uncoated particles would also fall outside the claim.
The word “comprising” gives the claim an open-ended transition. A formulation may contain additional excipients, coatings, particle populations, flavors, suspending agents, stabilizers, or other inactive ingredients. Those additions do not avoid the claim if the claimed elements remain present.
The claim does not require a particular dosage form, particle size, resin loading, coating thickness, manufacturing process, or release profile beyond the requirement that the second particle population have a delayed-release coating.
Claim 2: pH-triggered release
Claim 2 narrows claim 1 by requiring the delayed-release coating to be triggered by a pH change. This limitation targets enteric or pH-responsive release mechanisms.
A formulation with a purely time-dependent coating, osmotic mechanism, diffusion membrane, or enzyme-triggered system may fall outside claim 2. It could still infringe claim 1 if the coating qualifies as delayed release and all other claim elements are met.
Claim 3: Coating materials
Claim 3 identifies the permitted pH-responsive coating materials. The list includes:
- Cellulose acetate phthalate.
- Cellulose acetate trimellitate.
- Hydroxypropyl methylcellulose phthalate.
- Polyvinyl acetate phthalate.
- Carboxymethylethylcellulose.
- Copolymerized methacrylic acid and methacrylic acid methyl esters.
- Copolymerized methacrylic acid and acrylic acid ethyl esters.
- Mixtures of those materials.
This is a Markush limitation. A coating outside the listed chemical classes could avoid literal infringement of claim 3 while remaining potentially relevant to claims 1 or 2.
Claim 4: Resin chemistry
Claim 4 limits the resin to strong acidic cation-exchange resins, including:
- Polistirex.
- Polacrilex.
- Cholestyramine.
- Polacrilin.
- Mixtures of those resins.
The claim language identifies the resin by both functional category and named examples. A competing formulation using a weak-acid resin, a nonionic carrier, a lipid matrix, or a polymeric bead without ion-exchange functionality would have a stronger design-around position.
Claims 5 and 6: Preferred particle ratios
Claim 5 narrows the uncoated fraction to 40% to 50% and the coated fraction to 50% to 60%.
Claim 6 narrows the composition further to approximately:
- 45% uncoated drug-resin particles; and
- 55% coated drug-resin particles.
These claims are commercially important because they provide fallback positions if the broader percentage ranges in claim 1 are challenged for anticipation or obviousness.
Claim 7: Dosage forms
Claim 7 covers three dosage-form categories:
- Liquid suspension.
- Chewable composition.
- Orally disintegrating tablet.
The claim does not cover every possible oral dosage form as a matter of express language. A conventional swallowable tablet or capsule may not fall within claim 7, although it could still fall within claim 1 if the composition limitations are satisfied.
Claim 8: Amphetamine stereochemical ratio
Claim 8 requires a composition containing 25% levo-amphetamine and 75% dextro-amphetamine. This corresponds to the conventional mixed amphetamine salt ratio associated with products such as Adderall formulations and Dyanavel XR.
A formulation containing only dextro-amphetamine would not satisfy claim 8. A formulation using a materially different enantiomeric ratio could avoid claim 8 while still implicating claim 1.
Claim 9: Dose range
Claim 9 covers an ADHD-effective agent amount of 2 mg to 60 mg. This is a broad dosage range and is unlikely to be the principal technical barrier by itself. Its practical effect depends on how “amount” is construed, including whether the range applies to the total amphetamine base, amphetamine salts, or labeled dose per administration.
What products are most closely associated with US 8,709,491?
The patent is most closely associated with Dyanavel XR, an extended-release amphetamine oral suspension developed by Tris Pharma. FDA approved Dyanavel XR under NDA 205326 in 2015 for the treatment of attention-deficit/hyperactivity disorder. [3, 4]
| Product or technology |
Relationship to US 8,709,491 |
| Dyanavel XR |
Directly relevant Tris Pharma extended-release amphetamine product |
| Adderall XR |
Competing mixed amphetamine product using a different multiparticulate technology |
| Mydayis |
Competing mixed amphetamine product with extended-duration release |
| Vyvanse |
Competing lisdexamfetamine product; different active pharmaceutical ingredient and prodrug mechanism |
| Generic mixed amphetamine salts |
Potentially relevant only if the formulation uses the claimed resin-particle architecture |
| Methylphenidate products |
Therapeutic competitors but outside the amphetamine composition claims |
The patent does not cover lisdexamfetamine, methylphenidate, atomoxetine, guanfacine, or every mixed amphetamine salt formulation. Its commercial relevance is concentrated in extended-release amphetamine products using the claimed resin-based release platform.
What is the Orange Book status of US 8,709,491?
US 8,709,491 has been associated with FDA-listed patent protection for Dyanavel XR. The Orange Book records patents identified by the NDA holder for approved drug products and does not itself determine infringement or validity. [2]
The relevant regulatory characteristics are:
| Regulatory item |
Reported status |
| FDA product |
Dyanavel XR |
| Active ingredient |
Amphetamine, mixed dextro- and levo-amphetamine salts |
| Dosage form |
Extended-release oral suspension |
| NDA |
205326 |
| Sponsor |
Tris Pharma, Inc. |
| Patent |
US 8,709,491 |
| Reported patent expiration |
March 12, 2028 |
| Regulatory pathway for a generic |
ANDA, subject to applicable patent certifications |
The patent is a formulation patent. It is distinct from a method-of-use patent because the supplied claims are directed to a pharmaceutical composition and do not require a particular treatment step beyond the dose limitation in claim 9.
FDA Orange Book listing does not guarantee that every approved product presentation infringes every patent claim. Infringement depends on the formulation, particle ratios, resin chemistry, coating composition, dosage form, and dosage amount.
When does US 8,709,491 lose exclusivity?
The reported patent expiration date is March 12, 2028. A generic applicant could potentially enter before that date if:
- The patent is successfully invalidated.
- A court determines that the proposed product does not infringe.
- The patent is disclaimed or otherwise removed from the relevant listing.
- A Paragraph IV certification results in litigation that ends in a judgment or settlement permitting earlier launch.
- The generic product is approved after the patent expires.
FDA approval timing and market-entry timing are separate. An ANDA applicant may submit a Paragraph IV certification before patent expiration, but commercial launch can expose the applicant to patent litigation and a 30-month stay under the Hatch-Waxman framework if the NDA holder or patent owner files suit within the statutory period. [5]
Are there Paragraph IV challenges or generic entry risks?
The principal generic-entry risk is formulation substitution. A challenger would likely evaluate whether its product uses:
- Ion-exchange resin particles.
- The same or equivalent mixed amphetamine active ingredient.
- Separate uncoated and delayed-release particle populations.
- The claimed 20% to 50% and 50% to 80% ratios.
- A pH-triggered coating or one of the named coating materials.
- A liquid suspension, chewable product, or orally disintegrating tablet.
- The claimed 2 mg to 60 mg dosage range.
A generic developer could pursue a non-infringing formulation using a different release platform. Possibilities include a polymeric matrix, a diffusion-controlled coating, a different resin class, a single-particle population, or a different distribution of immediate- and delayed-release material.
A Paragraph IV challenge would also likely target validity. The most relevant arguments would involve:
- Obviousness based on known ion-exchange resin drug delivery systems.
- Anticipation by prior art disclosing mixed amphetamine resin complexes.
- Obviousness of combining immediate-release and delayed-release particle populations.
- Lack of written description for the full percentage ranges.
- Indefiniteness in terms such as “delayed release,” “triggered by a pH change,” and “ADHD effective agent.”
- Enablement across the full range of resins, coatings, dosage forms, and release conditions.
The narrow 45%/55% embodiment may provide stronger commercial and validity protection if supported by comparative release or pharmacokinetic data. The broad independent claim is more exposed to prior-art arguments because it covers a wider compositional range.
What patent litigation affects US 8,709,491?
The supplied patent claims do not establish a litigation outcome. The relevant litigation questions are whether a generic applicant has filed an ANDA with a Paragraph IV certification, whether Tris Pharma or another patent owner filed an infringement action, and whether a settlement permits an agreed launch date.
Public FDA patent listings identify the patent-product relationship but do not provide a complete litigation history. Patent litigation must be evaluated through federal district court dockets, appellate decisions, settlement filings, and FDA regulatory records. No litigation judgment or settlement term is established by the claim text itself.
A settlement involving this patent could include:
- A licensed early-entry date.
- A commitment not to launch until patent expiry.
- A supply or manufacturing arrangement.
- A covenant not to sue.
- A product-specific carve-out.
- Restrictions on the generic’s formulation or label.
No patent license or settlement right is created merely by the Orange Book listing.
How strong is the patent estate for Dyanavel XR?
US 8,709,491 has meaningful commercial scope but is not a complete barrier to all amphetamine competitors.
Strengths
- It covers a defined multiparticulate release design.
- It applies to multiple dosage forms.
- It covers several resin and coating classes.
- The dependent claims provide narrower fallback positions.
- The 45%/55% particle distribution may correspond to a commercially relevant formulation.
- The claim uses “comprising,” allowing additional excipients and formulation components.
Vulnerabilities
- The technology relies on known pharmaceutical ingredients and established ion-exchange resin techniques.
- Numerical particle ranges may be vulnerable to obviousness or anticipation arguments.
- The claim does not require a highly specific coating thickness, particle size, loading level, or dissolution profile.
- A competitor may design around the resin technology.
- The pH-triggered coating limitations apply only to narrower dependent claims.
- The patent does not cover all amphetamine products or all extended-release technologies.
The estate is strongest against a follow-on product that copies the same resin-based particle architecture and weakest against a product using a different release mechanism.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers include reproducible drug loading on resin particles, control of particle-size distribution, uniform coating of the delayed-release fraction, suspension stability, taste masking, dose uniformity, and control of amphetamine release across gastrointestinal pH conditions.
A competitor may face both patent and regulatory equivalence issues. For an ANDA product, the developer would need to demonstrate pharmaceutical equivalence and bioequivalence while avoiding the listed patent claims or prevailing in patent litigation. A formulation that is technically non-infringing may still require substantial development work to match Dyanavel XR’s release profile and approved labeling.
The strongest practical barrier is therefore the combination of formulation engineering, bioequivalence requirements, controlled-substance manufacturing requirements, and patent risk.
How does US 8,709,491 compare with competing amphetamine patents?
| Technology |
Active ingredient |
Release platform |
Main difference from US 8,709,491 |
| Dyanavel XR |
Mixed amphetamine salts |
Ion-exchange resin particles with uncoated and delayed-release populations |
Directly aligned with the patent |
| Adderall XR |
Mixed amphetamine salts |
Multiparticulate bead system |
Does not automatically use the claimed resin architecture |
| Mydayis |
Mixed amphetamine salts |
Extended-duration multiparticulate system |
Competing release profile and product design |
| Vyvanse |
Lisdexamfetamine |
Prodrug conversion mechanism |
Different active ingredient and mechanism |
| Generic immediate-release amphetamine |
Mixed amphetamine salts |
Immediate release |
Generally outside the delayed-release composition claims |
| Methylphenidate ER |
Methylphenidate |
Multiple release technologies |
Different stimulant and outside the claimed amphetamine composition |
What is the revenue exposure from US 8,709,491?
The patent’s direct revenue exposure is concentrated in Dyanavel XR and any other commercial product using the same patented formulation architecture. The claim set does not create a broad royalty position across the ADHD market because it does not cover competing active ingredients, all mixed amphetamine products, or all extended-release dosage forms.
Revenue risk increases as March 2028 approaches because an ANDA applicant may pursue a Paragraph IV challenge, a non-infringing formulation, or a post-expiration launch strategy. The commercial impact depends on Dyanavel XR sales, generic substitution rates, payer coverage, and the number of approved generic entrants.
Key Takeaways
- US 8,709,491 protects a mixed amphetamine drug-resin formulation.
- Claim 1 requires 20% to 50% uncoated drug-resin particles and 50% to 80% delayed-release drug-resin particles.
- Claim 6 identifies the preferred approximately 45% uncoated and 55% coated formulation.
- The patent covers liquid suspensions, chewable products, and orally disintegrating tablets through claim 7.
- Claim 8 covers the 25% levo-amphetamine and 75% dextro-amphetamine ratio.
- The patent is associated with Dyanavel XR and Tris Pharma.
- The reported expiration date is March 12, 2028.
- Generic risk centers on Paragraph IV challenges and alternative resin-free or non-pH-triggered release technologies.
- The patent is formulation-specific and does not broadly cover every extended-release amphetamine product.
- The most important validity issues are obviousness, prior-art resin systems, numerical particle ranges, and the breadth of the delayed-release limitations.
FAQs
Does US 8,709,491 cover Adderall XR?
Not automatically. Adderall XR is a competing mixed amphetamine product, but infringement depends on whether its formulation contains the claimed ion-exchange resin particles, uncoated and delayed-release particle populations, and required percentage ranges.
Can a generic avoid US 8,709,491 by changing the amphetamine ratio?
A materially different dextro-amphetamine/levo-amphetamine ratio could avoid claim 8, but it would not necessarily avoid claim 1, which requires only a mixture of dextro- and levo-amphetamines.
Does the patent cover an immediate-release amphetamine tablet?
Generally, the supplied claims target a resin-based composition with delayed-release particles. A conventional immediate-release tablet without the claimed resin-particle architecture would likely fall outside the literal scope.
Is a pH-sensitive coating required for every claim?
No. The pH-triggered coating is required by claim 2 and the coating-material limitations are further specified in claim 3. Claim 1 requires delayed release but does not expressly require pH triggering.
Can a product infringe if it uses a different ion-exchange resin?
Potentially. Claim 1 broadly requires ion-exchange resin particles, while claim 4 narrows the resin to specified strong acidic cation-exchange resins. A different resin may avoid claim 4 but could still implicate claim 1 depending on the remaining formulation elements.
References
-
United States Patent No. 8,709,491. (2014). Pharmaceutical compositions comprising amphetamine and methods of use thereof. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2015). Dyanavel XR approval and prescribing information. FDA.
-
Tris Pharma, Inc. (2015). Dyanavel XR: Prescribing information. Tris Pharma.
-
21 U.S.C. § 355(j). (2024). Abbreviated new drug applications and patent certifications. United States Code.
